As leader of Global Health and Manufacturing Services (GHMS), Emily Kaine engages U.S. and international stakeholders, funders, and donors, helping them understand critical needs and how USP can contribute. She leads USP’s support of global laboratories, regulatory bodies, and manufacturers striving to reach international standards, as well as the services and offerings USP provides to help strengthen the global supply chain.
Emily joined USP in 2014, launching the USP Strategy function. In 2016, she transitioned to lead the Global Health Division at USP, where she was responsible for growing USP’s international development portfolio. In 2020, her role expanded to include USP’s capability-building and services portfolio, GHMS, which, in addition to the global health work, includes USP Education, an Advanced Manufacturing services unit, and USP’s Federal Practice, dedicated to securing and implementing U.S.-based projects funded through domestic sources.
As Chair of the Board of Trustees for Pharmatech Associates, Emily supports the board in providing strategic guidance to the company, which is a wholly owned USP subsidiary providing leading edge consulting support to life sciences companies seeking to bring innovative therapeutics to market.
Emily has experience as a management consultant and has worked as a strategist for a large U.S. health system and a global pharmaceutical company.
- Carolinas Healthcare (now Atrium Health): Director of Planning
- Novartis Global Oncology: Director of Operations and Planning
- McKinsey: Engagement Manager, Healthcare
- Columbia University College of Physicians, M.D., Alpha Omega Alpha
- Harvard-Radcliffe College, Artium Baccalaureus, Phi Beta Kappa
- Supporting growth of USP’s global health portfolio towards advancing supply chain resiliency
- Helping to launch a new Federal Practice at USP, directed at advancing our efforts to help secure the U.S. pharmaceutical supply chain
- Supporting the acquisition of Pharmatech Associates, a wholly owned USP subsidiary, which supports life sciences companies to bring innovative therapeutics to market